DDInter629 DDInter122
Eliglustat is a glucosylceramide synthase inhibitor used for the long-term treatment of type 1 Gaucher disease.[A3752,L41404] Gaucher disease is a rare genetic disorder characterized by the deficiency of acid β-glucosidase, an enzyme that converts glucosylceramide into glucose and ceramide. In patients with Gaucher disease, the accumulation of glucosylceramide leads to the formation of Gaucher cells that infiltrate the liver, spleen, bone marrow and other organs. This leads to complications such as anemia and thrombocytopenia.[L41404,A246384] By inhibiting glucosylceramide synthase, eliglustat reduces the accumulation of glucosylceramide. Eliglustat is mainly metabolized by CYP2D6. Patients selected for eliglustat treatment undergo an FDA-cleared genotyping test to establish if they are CYP2D6 extensive metabolizers (
Artesunate is indicated for the initial treatment of severe malaria. The World Health Organization recommends artesunate as first line treatment for severe malaria. Artesunate was developed out of a need for a more hydrophilic derivative of [artemisinin]. Artesunate was granted FDA approval on 26 May 2020.
Eliglustat {u} may cause a minor interaction that can limit clinical effects when taken with {v} Donepezil
Eliglustat {u} may cause a minor interaction that can limit clinical effects when taken with {v} Naloxegol
Eliglustat {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Fenfluramine
Eliglustat {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Naldemedine
Eliglustat {u} may lead to a major life threatening interaction when taken with {v} Bepridil
Eliglustat {u} may lead to a major life threatening interaction when taken with {v} Dacomitinib
Eliglustat may cause a minor interaction that can limit clinical effects when taken with Donepezil
Eliglustat may cause a minor interaction that can limit clinical effects when taken with Naloxegol
Eliglustat may cause a moderate interaction that could exacerbate diseases when taken with Fenfluramine
Eliglustat may cause a moderate interaction that could exacerbate diseases when taken with Naldemedine
Eliglustat may lead to a major life threatening interaction when taken with Bepridil
Eliglustat may lead to a major life threatening interaction when taken with Dacomitinib